Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefotetan Therapy for Escherichia Coli Infections
NCT07318584Phase 2Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Escherichia coli infection comparing Cefotetan with Standard of care antibiotics (2 arms). Primary endpoint: Clinical success at 30 days. Started Jun 2026; status: recruiting.
02
Drugs
cefotetan
03
Conditions
Escherichia coli infection
Beyond the preview
Go deeper on NCT07318584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318584.